Saturday 17 October 2026
Export ZURA’s income statement to Excel — free account
Zura Bio Limited
ZURA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 23.5% and free cash flow fell 30.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.88
0.40
−9.35%
Follow ZURA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
9.05 | 9.16 | 4.97 | 0.12 | 0.02 | 4.23 | 4.23 | — |
Net Debt/EBITDA |
1.45 | 3.20 | 1.59 | 0.06 | 0.01 | 0.82 | 0.67 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.65 | 0.62 | 0.22 | 0.04 | (0.30) | (0.16) | (0.13) | — |
Capex/Depreciation |
(2.31) | (563.89) | 0.00 | 0.00 | — | — | — | — |
Interest Coverage |
— | — | — | — | — | — | (92.94) | — |
| (79.52%) | (43.38%) | (356.78%) | 207.38% | 0.00% | 11.32% | 0.00% | — | |
| (67.71%) | (32.38%) | (130.52%) | (44.43%) | 0.00% | 4.87% | 11.98% | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(99.33%) | (28.49%) | (85.97%) | 248.35% | (197.75%) | 778.43% | 956.66% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | — | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | — | — | — |
Free Cash Flow per Share |
(0.69) | (0.44) | (0.70) | (57.90) | (0.06) | (0.35) | (0.06) | — |
Cash per Share |
1.16 | 2.35 | 3.02 | 6.87 | 0.00 | 0.23 | 0.04 | — |
Shareholders Equity per Share |
1.08 | 1.98 | 1.84 | (41.91) | 7.75 | (2.93) | 7.55 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.08 | 1.98 | 1.84 | (41.91) | 7.75 | (2.93) | 7.55 | — |
Free Cash Flow |
(64.93) | (33.15) | (23.05) | (13.20) | (1.07) | (1.10) | (1.10) | — |
Working Capital |
99.90 | 159.23 | 80.54 | (13.04) | (1.79) | 0.88 | 0.88 | — |
Capital Expenditures |
(0.11) | (5.07) | (8.00) | (12.00) | — | — | — | — |
Net Current Asset Value |
99.90 | 147.57 | 60.87 | (13.04) | (7.73) | (148.58) | (9.20) | — |
| Other line items | ||||||||
Quick Ratio |
8.82 | 9.04 | 4.92 | 0.11 | 0.01 | 2.68 | 2.68 | — |
Depreciation/Fixed assets |
0.39 | 0.10 | — | — | — | — | — | — |
Cash ROIC |
(30.78%) | (10.20%) | (14.35%) | 165.25% | (0.80%) | 12.99% | (0.84%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.69) | (0.37) | (0.46) | (5.27) | (0.06) | (0.35) | (0.06) | — |
Capex per Share |
0.00 | (0.07) | (0.24) | (52.63) | 0.00 | 0.00 | 0.00 | — |
Average Payables |
15.96 | 19.91 | 10.33 | 0.22 | — | — | — | — |
Average Assets |
146.74 | 140.19 | 53.05 | 72.91 | 141.03 | 140.55 | 70.28 | — |
Average Common Equity |
124.95 | 104.61 | 19.41 | (15.62) | 62.28 | 60.51 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Columns are period end dates